Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Med Case Rep ; 16(1): 352, 2022 Oct 04.
Artículo en Inglés | MEDLINE | ID: covidwho-2053961

RESUMEN

BACKGROUND: As the coronavirus disease 2019 infections are still ongoing, there is an increasing number of case reports and case series with various manifestations of life-threatening multisystem inflammatory syndrome in children . Our case aims to remind all providers to scrutinize for clinical manifestations, including neurological symptoms, which may mimic aseptic meningitis. CASE PRESENTATION: A 5-year-old Albanian male child with obesity was admitted to the pediatric intensive care unit due to persistent fever, headache, vomiting, abdominal pain, mucocutaneous manifestations, and fatigue. Initial laboratory results revealed high level of inflammatory markers, including C-reactive protein of 156.8 mg/l, erythrocyte sedimentation rate of 100 mm/hour, procalcitonin of 13.84, leukocytosis with neutrophilia, and lymphopenia. Liver and renal functions, and capillary blood electrolytes (Na, K, Ca), were also altered. Cerebrospinal fluid was slightly turbid, with a white blood cell count of 128/mm3 (80% mononuclear cells and 20% polymorphonuclear), consistent with aseptic meningitis. The clinical presentation with prolonged fever, multiorgan dysfunction, and elevated inflammatory markers, with no plausible alternative diagnosis, matches the case definition of multisystem inflammatory syndrome in children. Combining corticosteroid methylprednisolone with intravenous immunoglobulin was effective. CONCLUSIONS: Apart from the most common presentation of multisystem organ dysfunction, neurological manifestations of multisystem inflammatory syndrome in children such as aseptic meningitis, may be present as an immune response post-viral to coronavirus disease 2019. Given the rapid deterioration of children with multisystem inflammatory syndrome, early treatment with immunoglobulins and corticosteroids should be considered.


Asunto(s)
COVID-19 , Enfermedades del Tejido Conjuntivo , Meningitis Aséptica , Proteína C-Reactiva/análisis , COVID-19/complicaciones , Niño , Preescolar , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Meningitis Aséptica/diagnóstico , Meningitis Aséptica/etiología , Metilprednisolona , Polipéptido alfa Relacionado con Calcitonina , SARS-CoV-2 , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico
2.
Acta Clin Belg ; 77(6): 976-979, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-1561677

RESUMEN

OBJECTIVE: Aseptic meningitis is a rare, but possible severe side effect after SARS-CoV-2 Pfizer/BioNTech vaccination. CASE PRESENTATION: Recently, a first case of aseptic meningitis after the first shot of mRNA-BNT162b2 SARS-CoV-2 (Pfizer/BioNTech) vaccine was reported. We present the first case of a 34-year-old woman without relevant medical history developing aseptic meningitis after her 2nd Pfizer/BioNTech vaccination. She was admitted with severe headache and fever for 5 days prior to her presentation at the emergency department. An extensive work-up of the clinical problem could narrow the differential diagnosis. Symptoms resolved after methylprednisolone therapy. CONCLUSION: This case highlights a rare but important side effect after vaccination that primary physicians and neurologists should be aware of in order to identify and efficiently manage these patients.


Asunto(s)
COVID-19 , Meningitis Aséptica , Femenino , Humanos , Adulto , Meningitis Aséptica/diagnóstico , Meningitis Aséptica/etiología , SARS-CoV-2 , Vacuna BNT162 , COVID-19/prevención & control , Vacunación , Metilprednisolona , ARN Mensajero
4.
Pediatr Infect Dis J ; 41(2): 172-174, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1494051

RESUMEN

Vaccination is currently the best strategy to control the coronavirus disease 2019 epidemic. This report describes a case of aseptic meningitis 3 weeks after administration of the second dose of Comirnaty. The patient recovered with conservative and symptomatic care after 5 days of admission. Surveillance of rare adverse events, including aseptic meningitis, and their management should be prompt and appropriate.


Asunto(s)
Vacuna BNT162/efectos adversos , Meningitis Aséptica/etiología , Adolescente , Humanos , Masculino , Meningitis Aséptica/terapia , SARS-CoV-2 , Resultado del Tratamiento , Tratamiento Farmacológico de COVID-19
5.
BMC Infect Dis ; 21(1): 746, 2021 Aug 03.
Artículo en Inglés | MEDLINE | ID: covidwho-1365324

RESUMEN

BACKGROUND: Varicella-zoster virus (VZV) is a known cause of aseptic meningitis, with a predisposition for an immunocompromised population. A dermatomal rash usually accompanies aseptic meningitis secondary to VZV. CASE PRESENTATION: We report the case of a 31-year-old male with a history of chickenpox in childhood and recent shingles who presented with severe frontal headaches secondary to VZV meningitis. The patient had also recently received the measles-mumps-rubella (MMR) vaccine. He recovered without any neurological sequala. CONCLUSION: This case report describes an immunocompetent patient with recent MMR vaccination who developed aseptic meningitis secondary to VZV without any dermatomal involvement (Zoster Sine Herpete).


Asunto(s)
Varicela , Exantema , Herpes Zóster , Meningitis Aséptica , Adulto , Herpes Zóster/diagnóstico , Herpesvirus Humano 3 , Humanos , Masculino , Meningitis Aséptica/diagnóstico , Meningitis Aséptica/etiología , Vacunación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA